Bortezomib Alvogen Use In Pregnancy & Lactation

The patient should not use Bortezomib Alvogen if she is pregnant, unless clearly necessary.
Women of childbearing potential must use effective contraception during treatment and for 8 months following completion of treatment. The patient must be advised to talk to the doctor if she wishes to freeze her eggs before starting treatment.
Men should not father a child while using Bortezomib Alvogen and should use effective contraception during treatment and for up to 5 months after treatment has stopped. The patient must be advised to talk to the doctor if he wishes to conserve the sperm before starting treatment.
The patient should not breast-feed while using Bortezomib Alvogen. The patient must be advised when it is safe to restart breast-feeding after finishing the treatment.
Thalidomide causes birth defects and foetal death. When Bortezomib Alvogen is given in combination with thalidomide, the patient must follow the pregnancy prevention programme for thalidomide (see package leaflet for thalidomide).